Some endocrine irAEs following anti-PD-1 therapies include hyper/hypothyroidism with two or more abnormal thyroid function tests (free thyroxine, free triiodothyronine, and thyroid stimulating hormone) (39), and adrenal insufficiency diagnosed by an adrenocorticotropic hormone stimulation test (57). The gene discussed is PDCD1; the disease is hypothyroidism.